Post-Exposure Prophylaxis -- How Well Do Health Care Providers Take Antiretroviral Therapy?
July 1, 1998
The objectives of this study were to examine the toxicity and tolerability of post-exposure prophylaxis (PEP), the impact of PEP on markers of HIV infection, and the epidemiology of exposures in a group of health care workers. 154 exposures to blood or body fluids were recorded, with 65 exposures from HIV-infected individuals. 131 of the 154 exposures were due to injuries from needlesticks, scalpels, or other sharp objects. Many exposures were associated with a higher risk of seroconversion -- there was blood observed on the sharp instrument in 81/154 injuries, the injury was phlebotomy related in 62/154 cases, the patient was terminally ill or known to have a high viral load in 7 instances, and four needlesticks were deep punctures.
Recommendations for PEP for those exposed to blood or bodily fluids of HIV patients included ZDV + 3TC for 38 providers, ZDV + 3TC + indinavir for 18, a combination of two other nucleosides and a protease inhibitor for two, and another dual nucleoside combination for 7. The number of health care providers who completed 7-, 14-, or the complete 28-day course of PEP therapy is shown in the table below.
Several important observations can be made from this study. First, a group of highly motivated individuals who understand that their therapy will be of limited duration cannot complete a full course of PEP. This is an important message for people who take care of HIV infected individuals -- these medications can be tough to take. Another important observation is that PEP may alter the time that an individuals develops an antibody response to HIV and the time until someone has a detectable PCR. Without PEP it was assumed that all individuals would seroconvert within six months of exposure if they were going to. Certainly, one would have anticipated that the HIV PCR would be detectable within that period of time. The individual who became infected had a negative antibody and HIV PCR six months following exposure after taking two weeks of PEP. One unanswered question in this case is whether the interferon therapy could have affected HIV replication resulting in a delay in seroconversion and viral replication that could be detected by PCR.
This article was provided by TheBodyPRO. It is a part of the publication The 12th International AIDS Conference.
The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.